

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number  
WO 03/061552 A2

- (51) International Patent Classification<sup>7</sup>: A61K
- (21) International Application Number: PCT/IN03/00009
- (22) International Filing Date: 13 January 2003 (13.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
27/MUM/2002 14 January 2002 (14.01.2002) IN  
27/MUM/2002 13 January 2003 (13.01.2003) IN

(71) Applicant (for all designated States except US): SUN PHARMACEUTICAL INDUSTRIES LIMITED [IN/IN]; ACME PLAZA, ANDHERI KURLA ROAD, ANDHERI (EAST), 400059 MUMBAI (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GANDHI, Biren, Jaiprakash [IN/IN]; SUN PHARMA ADVANCED RESEARCH CENTRE, AKOTA ROAD, AKOTA, 390020 BARODA (IN). SHAH, Samir, Rameshchandra [IN/IN]; SUN PHARMA ADVANCED RESEARCH CENTRE, AKOTA ROAD, AKOTA, 390020 BARODA (IN). CHITTURI, Trinadha, Rao [IN/IN]; SUN PHARMA ADVANCED RESEARCH CENTRE, AKOTA ROAD, AKOTA, 390020 BARODA (IN). THENNATI, Rajamanar [IN/IN]; SUN PHARMA ADVANCED RESEARCH CENTRE, AKOTA ROAD, AKOTA, 390020 BARODA (IN).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

## Published:

- without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: NOVEL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 5-(3,5-DIMETHYLPHENOXY)METHYL-2-OXAZOLIDINONE

(57) Abstract: Substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, a compound of formula (1), is prepared by a novel route, which comprises reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, a compound of formula (2), or its acid addition salt with a compound of formula (3) (YCOZ) wherein Y and Z are selected from X, CCl<sub>3</sub>CO, 1-imidazolyl or substituted imidazolyl, and OR; wherein X is a halide, preferably chloride, and R is selected from substituted or unsubstituted linear, branched or cyclic alkyl and aryl or heteroaryl radicals. The compound of formula (2) is prepared by treating 2-[(3,5-Dimethylphenoxy)methyl]oxirane with ammonia to yield compound of formula (2), and optionally purifying compound of formula (2) by converting to its acid addition salt.

WO 03/061552 A2

WO 03/061552 A2




*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**NOVEL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY  
PURE 5-(3,5-DIMETHYLPHENOXY)METHYL-2-OXAZOLIDINONE**

5

**FIELD OF THE INVENTION**

The present invention relates to a novel process for preparing substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, a compound of formula 1. 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, commonly known as metaxalone (INN Name), a  
10 compound of formula 1 is indicated as an adjunct to rest, physical therapy and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.



Formula 1

15

**BACKGROUND OF THE INVENTION**

United States Patent No. 3062827 generically claims 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone. This patent also discloses three methods for the preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, viz.  
20

- (a) reacting 3-(3,5-dimethylphenoxy)-1,2-propanediol with urea; or
- (b) reacting 3-(3,5-dimethylphenoxy)-1-chloro-2-propanol with urea; or
- (c) reacting 3-(3,5-dimethylphenoxy)-2-hydroxy-1-propyl-carbamate with urea.

The patent exemplifies the process at elevated temperature i.e. 195-200°C and also involves  
25 distillation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone under high vacuum and temperature. This patent does not disclose the purity of the prepared 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone; the process described is energy consuming and yields 79% product. When we carried out the patented process the purity of the crude product obtained

was only about 51% and unreacted 3-(3,5-dimethylphenoxy)-1,2-propanediol was found to be the major impurity. There is thus a need for a process wherein the starting material is efficiently converted to 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone.

5    **United States Patent No. 3446814** claims a method of preparing 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone by reacting triglycidyl isocyanurate with m-xyleneol. The patent exemplifies reacting the raw materials with pulverized sodium hydroxide in chlorobenzene at its reflux temperature which is 131-132°C for 13 hours in presence of benzyltrimethylammonium chloride, followed by recrystallization of the product from  
10 chlorobenzene. This patent does not disclose the purity of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone. The process is also energy consuming and yields 76% product.

A novel process has been found for the preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone from 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine. None of the methods  
15 disclosed in prior art prepare 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone by the process of the present invention. The novel process converts the starting material to the intended product in an efficient manner such that substantially all of the starting material is converted to the intended product.

20

#### **OBJECT OF THE INVENTION:**

The object of the present invention is to provide a novel process to prepare 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone.


25

The process of the present invention provides a novel process that prepares 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone in high yields in a substantially pure form.

Another object of the present invention is to provide substantially pure 3-(3,5-dimethylphenoxy)-  
30 2-hydroxypropylamine, compound of formula 2, or its acid addition salt and the process of its preparation.

**SUMMARY OF INVENTION :**


The present invention provides a novel process for the preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, compound of formula 1, comprising




Formula 1

reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, or its acid addition salt with a compound of formula 3,

10



Formula 2




Formula 3

wherein Y and Z are selected from X,  $\text{CCl}_3\text{CO}$ , 1-imidazolyl or substituted imidazolyl and OR;  
 15 wherein X is a halo radical, and R is selected from a substituted or unsubstituted linear, branched or cyclic alkyl radical, and aryl or heteroaryl radical.

The process of the present invention also provides for the purification of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, compound of formula 1, by crystallization of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) from an organic solvent system.


20

Particularly, the process of the preparation of compound of formula 1 comprises treating compound of formula 5 with a source of ammonia to yield compound of formula 2, optionally purifying compound of formula 2 by converting to its acid addition salt; and




Formula 5

reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, or its acid  
5 addition salt with a compound of formula 3.




Formula 2




Formula 3

- 10 More particularly the process of the present invention for the preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone encompasses
- (a) reacting 3,5-dimethylphenol, compound of formula 4, with epichlorohydrin and a base to obtain an oxirane, compound of formula 5;
  - (b) treating compound of formula 5 with a source of ammonia to yield compound of  
15 formula 2, optionally purifying compound of formula 2 by converting to its acid addition salt; and




Formula 4




Formula 5

- 20 (c) reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, or its acid addition salt with a compound of formula 3.




Formula 2



Formula 3

The present invention also provides a substantially pure 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, or its acid addition salt and the process of its preparation comprising treating compound of formula 5 with a source of ammonia to yield compound of formula 2, optionally purifying compound of formula 2 by converting to its acid addition salt.

10



Formula 5

The novel process of the present invention has been found to be advantageous in that the reactions involved can be carried out without substantial expenditure of energy, and the desired product, viz. 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) can be obtained in high yields in a substantially pure form.

As referred to herein substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone is 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone with purity greater than 99%.

Preferably the substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone has purity greater than 99.5%, more preferably greater than 99.9% by HPLC.

Most preferably, substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) has a purity greater than 99.5% and has no individual impurity that is more than 0.05% by HPLC.


- 5 As referred to herein substantially pure 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, is 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine with purity greater than 99% by HPLC.

#### DETAILED DESCRIPTION OF THE INVENTION:


10

A novel method of preparation was conceived and developed by us so as to obtain substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1).

- 15 The process of the present invention adopts a novel methodology to prepare 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone which comprises reacting, 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, a compound of formula 2, or its acid addition salt with compound of formula 3,



Formula 2



Formula 3

20

wherein Y and Z are selected from X,  $\text{CCl}_3\text{CO}$ , 1-imidazolyl or substituted imidazolyl, and OR; wherein X is a halo radical, and R is selected from a substituted or unsubstituted linear, branched or cyclic alkyl radical, and aryl or heteroaryl radical.


- 25 The substitutions on linear, branched or cyclic alkyl radical comprise of cyano, nitro, alkoxy, aryloxy, mercaptoalkyl, mercaptoaryl, alkyl or arylsulphonyl. The preferred substitutions are the electron withdrawing substituents like cyano or nitro.




The substitutions on aryl, heteroaryl or imidazolyl radical comprise of halo, cyano, nitro, alkoxy, aryloxy, mercaptoalkyl, mercaptoaryl, alkyl or arylsulphonyl. The preferred substitutions are the electron withdrawing substituents like halo, cyano or nitro.

- 5 In preferred embodiments, the compound of formula 3 is preferably a carbonate or a haloformate, most preferably a chloroformate.

The present invention also discloses a method for the preparation of 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, which comprises treating compound of formula 5  
10 with a source of ammonia to yield compound of formula 2, and optionally converting compound of formula 2 to its acid addition salt in order to isolate substantially pure compound of formula 2.



Formula 4



Formula 5

The acid addition salt of compound of formula 2 may be selected from its hydrochloride, sulfate  
15 or hydrobromide salt, preferably its hydrochloride salt, in order to isolate substantially pure form compound of formula 2.

As referred to herein substantially pure 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, is 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine with purity greater  
20 than 99%.


Details of each step are as given below:

#### Preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone


25

According to the process of the present invention, preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone is carried out by reacting 3-(3,5-dimethylphenoxy)-2-

hydroxypropylamine, compound of formula 2, or its acid addition salt in an organic solvent in the presence of a base, with a compound of formula 3,



Formula 2



Formula 3

5

wherein Y and Z are selected from X,  $\text{CCl}_3\text{CO}$ , 1-imidazolyl or substituted imidazolyl, and OR; wherein X is a halo radical, and R is selected from a substituted or unsubstituted linear, branched or cyclic alkyl radical, and aryl or heteroaryl radical.

In preferred embodiments of the invention the compound of formula 3 is a carbonate or a  
10 haloformate wherein Y is halo and Z is OR wherein R is selected from linear  $\text{C}_1$  to  $\text{C}_4$  alkyl radical, preferably a chloroformate, most preferably ethyl chloroformate.

The organic solvent is selected from polar and non-polar solvents comprising of aliphatic, cyclic or aromatic substituted or unsubstituted hydrocarbons such as benzene, toluene, xylene,  
15 cyclohexane, dichloromethane, dichloroethane, monochlorobenzene and the like; ketones such as acetone, methylisobutylketone, methylethylketone, cyclohexanone and the like; cyclic and acyclic ethers such as ether, tetrahydrofuran, dioxan, dimethoxyethane, diglyme and the like; polyethers such as poly(alkylene glycol)s and the like; nitriles such as acetonitrile, benzonitrile and the like; amides such as dimethylformamide, dimethylacetamide and the like. The preferred  
20 solvent is an aliphatic, cyclic or aromatic substituted or unsubstituted hydrocarbon, most preferably toluene.

The base for the reaction is selected from a group of organic or inorganic bases. The organic base may be selected from tertiary amines or aromatic bases, and the inorganic base may be selected  
25 from bicarbonates, carbonates, hydrides, hydroxides and oxides of alkali or alkaline earth metals. In preferred embodiments the base is an inorganic base, which is a carbonate of an alkali metal, the most preferred base being potassium carbonate.

In the process of the present invention, when the reaction is carried out using an inorganic base, addition of a facilitator has been found to be very advantageous. The facilitator is a substance that has the property to complex or solvate metal cations, for example, a polyether. Alternatively, the facilitator may be a substance that can

- 5     • exchange the metal cations with hydrophobic cations, for example, a quaternary ammonium salt or a quaternary ammonium hydroxide where substituents on the nitrogen are selected from alkyl or aralkyl groups, for example, benzyltrialkylammonium halide; or
- act in a fashion similar to phase transfer catalyst.
- 10    The facilitator may be selected from cyclic and acyclic polyethers. Cyclic ethers such as crown ethers and acyclic ethers such as poly(alkylene glycol) may be used. Poly(alkylene glycol) which may be used is poly(ethylene glycol) (PEG) with an average molecular weight in the range between 200 to 10,000, the most preferred facilitator for the reaction being PEG-400.
- 15    The reaction can be performed at temperatures ranging from 0 to 150°C for about 1 to 10 hours, preferably at 50 to 150°C for about 2 to 8 hours, the most preferred being about 100 to 110°C for about 5 hours.

For instance, the reaction is carried out by heating gradually to reflux a mixture of compound of  
20    formula 2, PEG-400 and an alkali metal carbonate in an organic solvent, cooled to ambient temperature and then ethyl chloroformate is added to it. The mixture is then heated for completion, to furnish the desired oxazolidinone (formula 1). The reaction mixture is worked up by standard methods known to those skilled in the art. The product is isolated with a yield of about 90%, and is greater than 99% pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone.

25

#### **Optional Further Purification of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone**

In another embodiment of the process of the present invention 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) is purified to greater than 99% purity to yield substantially pure 5-  
30    (3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) by recrystallization from a solvent, optionally by addition of a second solvent.

The solvent system which may be used in the purification step may comprise a mixture of solvents selected from a polar and non-polar organic solvent comprising of aliphatic, cyclic or aromatic substituted or unsubstituted hydrocarbons such as benzene, toluene, xylene, cyclohexane, dichloromethane, dichloroethane, monochlorobenzene and the like; alcohols such as C<sub>1</sub>-C<sub>6</sub> alcohols like methanol, ethanol, propanols, butanols and the like; diols, polyols selected from ethylene glycol, propylene glycol and the like; esters such as ethyl acetate, butyl acetate and the like; ketones such as acetone, methylisobutylketone, methylethylketone, cyclohexanone and the like; cyclic and acyclic ethers such as ether, tetrahydrofuran, dioxan, dimethoxyethane, diglyme and the like; polyethers such as poly(alkylene glycol) and the like; nitriles such as acetonitrile, benzonitrile and the like; amides such as dimethylformamide, dimethylacetamide and the like, sulfoxides such as dimethyl sulfoxide and the like. The preferred solvent system mixture for purification to achieve substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone is a mixture comprising acetone and toluene, in the ratio ranging from 0.5 : 1.0 to 1 : 10, most preferably in the ratio 1 : 1.

Preferably, for recrystallization, the dissolution is carried out at about ambient to 110°C, more preferably about 50 to 80°C.

Optionally, to the clear solution may be added another solvent and cooled gradually or spontaneously to about 0 to 30°C, preferably to 15 to 25°C.

The crystallized product is filtered, washed with a solvent and dried using conventional techniques known to those skilled in the art to yield substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone with purity greater than 99.9% by HPLC.

The substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone has purity greater than 99.5% and has no individual impurity that is more than 0.05% by HPLC.

In the preferred process of the present invention crystallization is allowed to occur by chilling or seeding or scratching the glass of the reaction vessel or cooling and other such common techniques, preferably cooling.

- 5 The product may be dried using different techniques of drying like fluid bed drying, tray drying and rotatory drying techniques with or without application of vacuum and / or under inert conditions.

**Preparation of 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine :**

10

Step (a) -Preparation of 3-[(3,5-dimethylphenoxy)methyl]oxirane:

- According to the process of the present invention step (a) is carried out by reacting 3,5-dimethylphenol with epichlorohydrin and a base in a solvent, optionally in the presence of a  
15 facilitator.

- The facilitator may be selected from quaternary ammonium salts such as benzyltrimethylammonium chloride and the like, or from cyclic and acyclic polyethers. Cyclic ethers such as crown ethers and acyclic ethers such as poly(alkylene glycol) may be used.  
20 Poly(alkylene glycol) which may be used is poly(ethylene glycol) (PEG) with an average molecular weight in the range between 200 to 10,000, preferably 200 to 1000, the most preferred being 400.

- The solvent for the reaction could be an aliphatic, cyclic or aromatic substituted or unsubstituted  
25 hydrocarbons such as benzene, toluene, xylene, cyclohexane, dichloromethane, dichloroethane, monochlorobenzene and the like. In preferred embodiment, the solvent is a polar solvent comprising of cyclic and acyclic ethers such as ether, tetrahydrofuran, dioxan, dimethoxyethane, diglyme and the like; polyethers such as poly(alkylene glycol)s (PEG) such as PEG-200, PEG-400 and the like; nitriles such as acetonitrile, benzonitrile and the like; amides such as  
30 dimethylformamide, dimethylacetamide and the like, sulfoxides such as dimethyl sulfoxide and

the like. In the present invention the preferred solvent is a water soluble ether, most preferably PEG-400, wherein no additional facilitator is required.

5 The base used could be selected from an organic or inorganic base, preferably an inorganic base selected from bicarbonates, carbonates, hydrides, hydroxides and oxides of alkali or alkaline earth metals. Most preferably the base is potassium hydroxide.

Further, the reaction may be carried out at about 20 to 80°C. The preferred temperature of step (a) may be 25 to 60°C, the most preferred being 35 to 45°C

10

The reaction may be carried out in poly(ethylene glycol)-400 in the presence of a base.

The reaction may be carried out in poly(ethylene glycol)-400 in the presence of potassium hydroxide at 35 to 45°C.

15

The reaction mixture is worked up by standard methods known to those skilled in the art.

Step (b) -Preparation of 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine:

20 According to the process of the present invention step (b) is carried out by reacting 2-[(3,5-dimethylphenoxy)methyl]oxirane with ammonia, preferably in a solvent. Ammonia could be used in the form of liquor ammonia, liquid ammonia or ammonia gas.

According to one embodiment of the present invention the organic solvent is selected from polar  
25 solvents like; alcohols such as C<sub>1</sub>-C<sub>6</sub> alcohols like methanol, ethanol, propanols, butanols and the like; diols, polyols selected from ethylene glycol, propylene glycol and the like; ketones such as acetone, methylisobutylketone, methylethylketone, cyclohexanone and the like; cyclic and acyclic ethers such as ether, tetrahydrofuran, dioxan, dimethoxyethane, diglyme and the like; polyethers such as poly(alkylene glycol)s and the like; nitriles such as acetonitrile, benzonitrile  
30 and the like; amides such as dimethylformamide, dimethylacetamide and the like, sulfoxides

such as dimethyl sulfoxide and the like. When liquor ammonia is used polar water soluble solvents are preferred.

In a preferred embodiment of the present invention organic solvent is an alkanol selected from  
5 C<sub>1</sub> to C<sub>4</sub> alkanol or its admixture with water. More preferably the alkanol is methanol.

Preferably, step (a) is carried out by adding a solution of 2-[(3,5-dimethylphenoxy)methyl]oxirane in methanol to a stirred solution containing large molar excess of liquor ammonia and methanol slowly over a period of about 9 hours while maintaining the  
10 temperature of about 25 to 30°C.

The reaction mixture is worked up by standard methods known to those skilled in this art. For instance, in a specific embodiment after completion of reaction methanol was distilled out below 60°C under vacuum. The product was extracted into methylene dichloride and the organic extract  
15 was acidified with conc. HCl added till about pH 2 to precipitate the product selectively as a hydrochloride salt devoid of impurities, which could be easily filtered to get 99% pure 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine hydrochloride.

The invention is illustrated but not restricted by the description in the following example.

20

25

30

**EXAMPLES****Example – 1****(a) Preparation of 2-[(3,5-Dimethylphenoxy)methyl]oxirane (formula 5)**

5 To a stirred solution of 3,5-dimethylphenol (100g, 0.818 mol.), PEG-400 (300ml), epichlorohydrin (128.01ml, 1.63mol) at 25-30° C is added one part of potassium hydroxide (18.37 g, 0.32mol.). Two more lots of potassium hydroxide (18.37 g each, 0.64mol.) are charged, each after an hour's interval after cooling the mixture to 25-30° C. The mixture was then stirred further for an hour of at 35-45° C. Water (400ml) is slowly added and the product is extracted  
10 into hexane (2 x 200ml) and (1x100ml). The combined hexane extract is concentrated at 60-65° C under vacuum. Any excess epichlorohydrin in the residue is finally stripped off by adding toluene (50.0ml) and degassing at 60-65°C under vacuum. Yield of the product is 142.0g.

**(b) Preparation of 3-(3,5-Dimethylphenoxy)-2-hydroxypropylamine hydrochloride (formula 2)**

15 A solution of 2-[(3,5-dimethylphenoxy)methyl]oxirane (100.0 g, 0.561mol) in methanol (300.0ml) is added slowly during about 9hrs, to a stirred solution containing liquor ammonia (1150ml) and methanol (700ml) while maintaining the temperature between 25-30°C. After completion of addition, the mixture is stirred for a further 1 hr and the methanol was distilled out  
20 under reduced pressure at below 60° C. The product is then extracted into methylene dichloride (1x 300ml. & 1 x 200ml.). Pooled extracts are washed with water (2x 250ml). The organic layer is dried over anhydrous sodium sulfate, cooled to 5-10°C and conc. HCl is added until the pH is about 2.0. The precipitated hydrochloride salt is filtered, washed successively with methylene dichloride (100.0ml) and hexane (50.0ml). Product is finally dried in air oven at 75-80° C to  
25 yield 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine hydrochloride, 62.0g (purity > 99.0%)

**(c) Preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1)**

A mixture of PEG-400 (50ml), toluene (500ml), potassium carbonate powder (89.6g, 0.648mol),  
30 and 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine hydrochloride (formula 3) (50g, 0.216mol) is heated gradually to reflux during 1.0 hr., and then azeotropically refluxed for 3hrs. The



- mixture is then cooled to 25-30°C and ethyl chloroformate (formula 4) (24.8g, 0.228mol.) is added gradually during 6 hrs. while maintaining the temperature below 40° C during the addition. The reaction mixture is then heated at 50-55°C for 2 hours. The temperature is raised to reflux and then refluxed azeotropically for 5.0hrs using Dean-Stark condenser. The mixture is then cooled to 10-15°C, water (150ml) is added and the pH is adjusted to 6.5-7.0 by gradual addition of conc. HCl. After stirring at 10-15°C for 1 hr. the product is separated by filtration and washed with toluene (2x 25ml), followed by water until washings are free from chloride, and dried. The toluene layer from the filtrates is separated, washed with water (2x100ml). It is concentrated to one tenth of the volume, cooled to 25-30°C and the crystallized second crop is filtered. Yield of product 43.0g (90%, purity >99% by HPLC).

**(d) Purification of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1):**

- 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1), (5g) obtained in example 1(c) is dissolved in acetone (15ml) by heating to 60-65° C. To the clear solution is added toluene (15ml), cooled gradually to 20-25° C and stirred for 2 hrs. at this temperature. The crystallized product is filtered, washed with toluene (5 ml) and dried to get 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) with purity of 99.93% (having a maximum single impurity of 0.02%).

**Example 2 : Method for analysis of purity by HPLC**

**Buffer :**

Dissolve 1.36g potassium dihydrogenorthophosphate in 1000ml of water. Take 650ml of buffer add 2ml of triethylamine. Adjust pH to 2.5 by orthophosphoric acid.

**Mobile phase:**

- Mix buffer solution and acetonitrile in the ratio of 650 : 350. Filter and degas prior to use.

**Sample preparation:**

Transfer about 100mg accurately weighed sample into a 100ml volumetric flask. Dissolve in and dilute upto mark with mobile phase.

**System suitability solution:**

- Transfer about 10mg of metaxalone into a 100ml volumetric flask. Dissolve in and dilute upto mark with mobile phase.

**Chromatographic system:**

The liquid chromatograph is equipped with a 225nm UV detector and 25 cm x 4.6 mm, 5micron column that contains Hypersil BDS C8. The flow rate is about 1.0 ml/min.

**Procedure:**

- 5 Inject 10 ml of system suitability solution into the system and record the chromatograms upto 25 min. Calculate the tailing factor of metaxalone peak. It should not be more than 1.5 and number of theoretical plates should not be less than 5000.

Inject 10 ml of sample preparation into the system and record the chromatograms upto 25 min.

- 10 The retention time of metaxalone is 13min. Calculate the amount of related substances by area normalization method, while disregarding any peak with an area percentage less than 0.025.

15


20

25

30


## We claim:

1. A novel process for the preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) comprising




Formula 1

reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, or its acid addition salt with a compound of formula 3,



Formula 2




Formula 3


wherein Y and Z are selected from X,  $\text{CCl}_3\text{CO}$ , 1-imidazolyl or substituted imidazolyl, and OR; wherein X is a halo radical, and R is selected from a substituted or unsubstituted linear, branched or cyclic alkyl radical, and aryl or heteroaryl radical.

2. A process as claimed in claim 1 wherein the reaction is carried out in the presence of a base.
3. A process as claimed in claim 2 wherein the base is potassium carbonate.
4. A process as claimed in claim 1 wherein in the compound of formula 3 Y is a halo radical and Z is OR wherein R is a linear  $\text{C}_1$  to  $\text{C}_4$  alkyl radical.
5. A process as claimed in claim 4 wherein the compound of formula 3 is ethyl chloroformate.
6. A process as claimed in claim 1 wherein the reaction is carried out in the presence of a facilitator.

7. A process as claimed in claim 6 wherein the facilitator is selected from cyclic and acyclic polyethers.
8. A process as claimed in claim 7 wherein the facilitator is poly(ethylene glycol) with an average molecular weight in the range between 200 to 10,000.
- 5 9. A process as claimed in claim 1 wherein the molar ratio of compound of formula 2 to compound of formula 3 is in the range of about 1:0.8 to 1:1.5.
- 10 10. A process as claimed in claim 1 wherein the 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) is obtained in a substantially pure form and has a purity greater than 99%.
11. A process for purifying 5-(3,5- dimethylphenoxy)methyl-2-oxazolidinone (formula 1) by crystallizing 5-(3,5- dimethylphenoxy)methyl-2-oxazolidinone (formula 1) from an organic solvent system.
12. A process as claimed in claim 11 wherein the 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) is obtained in a substantially pure form and has a purity greater than 99.5%.
- 15 13. A process as claimed in claim 11 wherein the 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) is obtained in a substantially pure form and has a purity greater than 99.9%.
14. A process as claimed in claim 11 wherein the 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) is obtained in a substantially pure form and has a purity greater than 99.5% and no individual impurity that is more than 0.05%.
- 20 15. A process as claimed in claim 11 wherein the organic solvent system is a mixture of acetone and toluene.
16. A process as claimed in claim 15 wherein the volume ratio of acetone : toluene is about 0.5 : 1.0 to 1 : 10.
- 25 17. A process for the preparation of 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, comprising




formula 2



formula 5

treating compound of formula 5 with a source of ammonia to yield compound of formula 2, optionally purifying compound of formula 2 by converting to its acid addition salt.


- 5 18. A process as claimed in claim 17 wherein the source of ammonia is selected from liquor ammonia, liquid ammonia and ammonia gas.
19. A process as claimed in claim 17 wherein the acid addition salt of compound of formula 2 is isolated in substantially pure form.
20. Substantially pure compound of formula 2 or its acid addition salt.




formula 2

21. A process for the preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) comprising

- a. reacting 3,5-dimethylphenol, compound of formula 4, with epichlorohydrin and a base to obtain an oxirane, compound of formula 5;
- b. treating compound of formula 5 with a source of ammonia to yield compound of formula 2, optionally purifying compound of formula 2 by converting to its acid addition salt; and




Formula 4




Formula 5

- c. reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, or its acid addition salt with a compound of formula 3.



Formula 2



Formula 3


5

wherein Y and Z are selected from X,  $\text{CCl}_3\text{CO}$ , 1-imidazolyl or substituted imidazolyl, and OR; wherein X is a halo radical, and R is selected from a substituted or unsubstituted linear, branched or cyclic alkyl radical, and aryl or heteroaryl radical.


22. A process as claimed in claim 21 wherein in step (a) the reaction of 3,5-dimethylphenol, epichlorohydrin and a base to obtain an oxirane derivative of formula 5, is carried out in the presence of a facilitator.
23. A process as claimed in claim 22 wherein the facilitator is selected from cyclic and acyclic polyethers.
24. A process as claimed in claim 23 wherein the acyclic polyether is poly(ethylene) glycol with an average molecular weight in the range between 200 to 10,000.
25. A process for the preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) comprising

- (a) reacting 3,5-dimethylphenol, compound of formula 4, with epichlorohydrin and a base to obtain an oxirane, compound of formula 5;
- (b) treating compound of formula 5 with a source of ammonia to yield compound of formula 2, optionally purifying compound of formula 2 by converting to its acid addition salt; and

20




Formula 4




Formula 5

25

- (c) reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, or its acid addition salt with a compound of formula 3, and



Formula 2




Formula 3

wherein Y and Z are selected from X,  $\text{CCl}_3\text{CO}$ , 1-imidazolyl or substituted imidazolyl, and OR; wherein X is a halo radical, and R is selected from a substituted or unsubstituted linear, branched or cyclic alkyl radical, and aryl or heteroaryl radical.


- (d) purifying 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) by crystallizing 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) from an organic solvent system.

26. A process for the preparation of 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) comprising treating compound of formula 5 with a source of ammonia to yield compound of formula 2, optionally purifying compound of formula 2 by converting to its acid addition salt; and



Formula 5

reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, compound of formula 2, or its acid addition salt with a compound of formula 3,



Formula 2

Formula 3

wherein Y and Z are selected from X, CCl<sub>3</sub>CO, 1-imidazolyl or substituted imidazolyl, and OR; wherein X is a halo radical, and R is selected from a substituted or unsubstituted linear, branched or cyclic alkyl radical, and aryl or heteroaryl radical.

27. A process as claimed in claim 26 further comprising purifying 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) by crystallizing 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone (formula 1) from an organic solvent system.



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IN 03/00009-0

## CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup>: C07D 263/24

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>7</sup>: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT, Chemical Abstracts

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO:WPI, STN:CAPLUS, REG

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 1163328 (Robins Company) 12 November 1959 (12.11.59) <i>claim 1, column 3, lines 11-43.</i>	1,2,11
X	C.D.Lunsford et al. 5-Aryloxymethyl-2-oxazolidinones. J.of the American Chemical Society. June 1959. Vol.82, pages 1166-71. <i>page 1166, right column, last paragraph; page 1169, right column, first paragraph.</i>	1,2
X	Merchant, J. R., Choughuley, A.S.U. . Reactions of epichlorohydrine with phenols. Current Science . November 1961, Vol.30, No.3, pages 99 and 100.	17, 20-27

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

„A“ document defining the general state of the art which is not  
considered to be of particular relevance

„R“ earlier application or patent but published on or after the international  
filing date

„L“ document which may throw doubts on priority claim(s) or which is  
cited to establish the publication date of another citation or other  
special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other  
means

„P“ document published prior to the international filing date but later than  
the priority date claimed

„T“ later document published after the international filing date or priority  
date and not in conflict with the application but cited to understand  
the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be  
considered novel or cannot be considered to involve an inventive step  
when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be  
considered to involve an inventive step when the document is  
combined with one or more other such documents, such combination  
being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

15 October 2003 (15.10.2003)

Date of mailing of the international search report

16 February 2004 (16.02.2004)

Name and mailing address of the ISA/AT

Austrian Patent Office

Dresdner Straße 87, A-1200 Vienna

Facsimile No. 1/53424/535

Authorized officer

BÖHM K.

Telephone No. 1/53424/519

# INTERNATIONAL SEARCH REPORT

Information on patent family members.

International application No.

PCT/IN 03/00009-0

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
A				none			
DE	B	1163328	1964-02-20	FR	A	1368707	1964-08-07
				GB	A	888594	1962-01-31
				CH	A	414640	1966-06-15
				CH	A	390916	1965-04-30
				DK	B	121709B	1971-11-22